Evidence map›Paper›PMID 32336599›Full record

ArticleVaccine2020

Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort.

Felix Sayinzoga, M Chantal Umulisa, Hassan Sibomana, Vanessa Tenet, Iacopo Baussano, Gary M Clifford

Registry-linked trialAbstract read
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06536855 (Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening), which is not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06536855 phase4unknown statusnot on this mapstarted 2024, after this paper: background citation

Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda

TypeinterventionalSponsorRwanda Biomedical CentreRan2024 to 2026Enrolled100,000ConditionsCervical CancerArmsGardasil 9
3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Global disparities in gynecologic cancer outcomes: A call for action.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Felix SayinzogaMinistry of Health, Rwanda Biomedical Center, Kigali, Rwanda.
M Chantal UmulisaInternational Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France; Université Claude Bernard Lyon 1, Lyon, France.
Hassan SibomanaMinistry of Health, Rwanda Biomedical Center, Kigali, Rwanda.
Vanessa TenetInternational Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France.
Iacopo BaussanoInternational Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France.
Gary M CliffordInternational Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. Electronic address: cliffordg@iarc.fr.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundIn 2011, Rwanda became the first African nation to implement a national human papillomavirus (HPV) vaccination program, conceived to protect girls aged <15 years (i.e. born ≥1997). After an initial school-grade-targeted catch-up campaign, there was a transition to routine vaccination of 12 year-olds only. We aimed to produce population-level vaccine coverage estimates.

methodsThe Rwandan Expanded Program on Immunization (EPI) collected data on number of eligible girls and HPV vaccines delivered, stratified by calendar year (2011-2018), girl's age, district and vaccination round. HPV vaccine coverage was estimated by birth cohort (reconstituted using calendar year and age), as a proportion of (1) eligible target, and (2) the 2012 Rwandan census population.

results1,156,863 girls received first dose of HPV vaccine between 2011 and 2018, corresponding to 98% of the eligible target. Median vaccination age was 15 years (interquartile range [IQR] 13-16) in 2011-2013 (school grade-targeted catch-up), 13 years (IQR 12-14) in 2014 (transition) and 12 years in 2015-2018 (routine). Population-level coverage versus the census increased from 10 to 40% for girls born in 1993-1995 (median vaccination age = 17 years) to 50-65% for 1996-2000 birth cohorts (14 years), and 80-90% for 2001-2006 birth cohorts (12 years). Coverage trends were similar across provinces and in the capital, Kigali. Second and third round coverage suggested most vaccinated girls completed their recommended dosing regimen (which reduced from 3 to 2 doses in 2015).

conclusionsBirth cohorts provide a clear picture of population-level HPV vaccine coverage after a pragmatic catch-up campaign, particularly in Rwanda where eligible school grades included wide age ranges. Whilst the catch-up campaign resulted in some coverage gaps in out-of-school teenagers, coverage remains high in cohorts routinely targeted as 12 year-olds.

Indexed as

Papillomavirus InfectionsAdolescentChildFemaleHumansImmunization ProgramsPapillomavirus VaccinesRwandaSchoolsVaccination CoveragePapillomavirus VaccinesCervical cancerCoverageHuman papillomavirusRwandaVaccine

Identifiers

PMID32336599
PMCPMC7221340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.